Boehringer Ingelheim

From Wikipedia, the free encyclopedia
Jump to: navigation, search
C. H. Boehringer Sohn AG & Co. KG
Industry Pharmaceuticals
Founded Ingelheim am Rhein, Germany (1885 (1885))
Headquarters Ingelheim, Germany
Key people
  • Andreas Barner, Chairman of the board
  • Hubertus von Baumbach, board member
  • Wolfgang Baiker, board member
  • Allan Hillgrove, board member
  • Joachim Hasenmaier, board member
Products Human Pharmaceuticals and Animal Health
Revenue Increase13.3 billion (2014)
Increase2.14 billion (2014)
Total assets Increase20.05 billion (2014)
Total equity Increase8.111 billion (2014)
Number of employees
47,743 (2014)
Slogan Value through Innovation

C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim GmbH, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. The company's key assets of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.[1]


Boehringer Ingelheim works in human pharmaceuticals, animal health and biopharmaceuticals. The group consists of 146 affiliated companies with 47,743 employees in 2014 in all continents. Research and development facilities were in five sites and 20 production plants in 13 countries. The research and development facilities are located in Biberach (Germany), Ridgefield (Connecticut), Vienna, Kobe, and Milan. Over 8,000 employees work for Boehringer Ingelheim in research and development.

Company History[edit]

In July 2015, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $2.65 billion ($1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $125 million based on performance milestones.[2][3] On the same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713, a third generation treatment for EGFR mutation-positive lung cancer.[4] Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's.[5]


  • 1885: Albert Boehringer buys a small tartar factory in Ingelheim am Rhein; work begins on 1 August.[citation needed]
  • 1886: The factory commences production of tartaric acid for use in the food industry (e.g. in baking powder and carbonated beverages).
  • 1893: Albert Boehringer renames the company C. H. Boehringer Sohn (CHBS) after his father, Christoph Heinrich Boehringer.[citation needed]
  • 1893: While experimenting with the production of citric acid, lactic acid is formed. Albert Boehringer develops this process, with the intention of producing lactic acid on a larger scale.
  • 1895: Lactic acid is produced on an industrial scale, and is successful commercially.
  • 1917: Professor Heinrich Wieland, chemist, future Nobel Prize winner and cousin of Albert Boehringer, sets up the company’s research department.
  • 1928: Albert Boehringer purchases Dr. Karl Thomae, a company based in Winnenden near Stuttgart.[citation needed]
  • 1946: Dr. Karl Thomae GmbH is re-opened in Biberach an der Riss with a staff of 70 people.
  • 1954: The company hires former Nazi Fritz Fischer after he is released from jail. Fischer was convicted of war crimes and crimes against humanity at the Nuremberg Trials.
  • 1955: The Animal Health division is established as the company acquires Pfizer’s veterinary programme.
  • 1971: The foreign subsidiary, Boehringer Ingelheim Pharmaceuticals, Inc is founded in Ridgefield, Connecticut (USA). This site is soon expanded, and becomes the company’s North American research centre.
  • 1985: The Institute for Molecular Pathology (IMP) is established in Vienna; it opens in 1988.
  • 1986: The biotechnological centre in Biberach begins production of biopharmaceuticals from cell cultures.[citation needed]
  • 1998: The merging of Boehringer Ingelheim KG and Dr. Karl Thomae GmbH founds Boehringer Ingelheim Pharma KG.
  • 2010: The company celebrates its 125th anniversary.

Collaborative research[edit]

Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[6][7] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[8]

Operational/development sites[edit]

Boehringer Ingelheim is a globally operating company, with 146 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology[5] in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.[citation needed] The company's generic pharmaceutical business is vested in the Ohio, United States-based Roxane Labs subsidiary.[9]

Closure of drug manufacturing plant[edit]

In 2011 Ben Venue Laboratories in Bedford, Ohio, a division of Boehringer Ingelheim, voluntarily shut down after a U.S. Food and Drug Administration inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid', later found to be urine.[10][11] The company invested US$300 million to upgrade the drug manufacturing plant, and limited production resumed in October 2012.[11] However, on 3 October 2013, Ben Venue announced that it would be ceasing production by the end of 2013 due to being unable to "return to sustainable production".[12]


In 2015, the Top Employers Institute [1] awarded the company as top employer in Austria, China and Germany, which demonstrates highest standards of employee offerings and forward-thinking human resources programmes and initiatives. In addition, the company was recognized by Science Magazine for the tenth consecutive year as a top company to work for in the pharmaceutical and biotechnology industries.

Universum [2] surveys reveals: the company is one of Germany's most attractive employers amongst Natural Sciences [3], Business [4] and Engineering [5] students 2015, e.g. ranked within the Top 10 in Natural Sciences. In the 2015 Trendence Graduate Barometer [6] 30.000 students were asked to evaluate their ideal future employer – Boehringer Ingelheim was one out of 100 preferred employers. Furthermore, in the 2014 Trendence Pupil Barometer [7], Boehringer Ingelheim has been awarded as employer of choice amongst pupils.

Boehringer Ingelheim’s trainee-programme [8] was honoured as a career-enhancing and fair programme by Absolventa [9]. The company was ranked number 1 in the “Praktikantenspiegel” [10] a survey amongst 7,500 interns for employer quality in the pharmaceutical industry. Boehringer Ingelheim has been awarded with the certificate “Beruf und Familie” [11] (Job and Family) for being a family-oriented company Ingelheim#839.

The company was awarded for its long-term-oriented human resources management by chemical-industry executives in the “VAA-Befindlichkeitsumfrage” [12] 2014. Boehringer Ingelheim’s corporate health management was awarded with the Corporate Health Award 2013 [13] and the Felix Burda Award 2015 [14]. In 2014, the company won the HR Excellence Award [15] in the category best leadership-development programme.

Key product lines[edit]

Prescription Medicine:

Consumer Health Care:

Animal Health:

Product pipeline[edit]

Boehringer Ingelheim's product pipeline targets lung disease, cancer, and hepatitis C.[13]

Drug Name Description Potential Indication Testing Phase
Olodaterol Long-acting beta-agonist Chronic obstructive pulmonary disease (COPD) Approved
Tiotropium Long acting muscarinic antagonist Cystic fibrosis (CF) / asthma. Already approved for chronic obstructive pulmonary disease (COPD) Approved
Nintedanib Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR Idiopathic pulmonary fibrosis (IPF) / non-small cell lung cancer (NSCLC) / ovarian cancer Phase III
Afatinib Irreversible ErbB family blocker Breast cancer / head and neck cancer. Already approved for non-small cell lung cancer (NSCLC) Phase III
Volasertib PLK1 antagonist Various cancer types Phase III
Deleobuvir (formerly BI 207127) NS5B RNA-dependent polymerase inhibitor Hepatitis C Phase III
Faldaprevir (formerly BI 201335) NS3/4A protease inhibitor Hepatitis C Phase III
Empagliflozin SGLT-2-inhibitor Diabetes mellitus type II Approved[14]
Idarucizumab Humanized antibody fragment (FAB), specific reversal agent to dabigatran Reversal of dabigatran-induced anticoagulation in case of an emergency Phase III


In October 2012 Boehringer Ingelheim settled a "qui tam" (whistleblower) case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.[15]

In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On 28 May 2014, a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug.[16]

In Popular Culture The Company is mentioned as being a former place of work for one of the Characters in Season Two, Episode Ten, of the Scandinavian Police thriller Series, The Bridge (Danish/Swedish TV series).

See also[edit]


  1. ^ "Boehringer Ingelheim Logo". Famous Logos. Retrieved 18 August 2011. 
  2. ^ Fourcade, Marthe (28 July 2015). "Hikma to Buy Boehringer Ingelheim's Roxane for $2.65 Billion". Bloomberg. 
  3. ^
  4. ^
  5. ^
  6. ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490. 
  7. ^ "InnoMed PredTox". Genedata. InnoMed PredTox Members. Retrieved 28 November 2014. 
  8. ^ Innovative Medicines Initiative. "IMI Call Topics 2008" (PDF). EUROSFAIRE. France: Ministry of Higher Education and Research. Retrieved 2008-08-25. 
  9. ^ Staff (15 January 2015). "Boehringer May Sell U.S. Generics Unit". Pharmaceutical Manufacturing (Putman Media). Bloomberg. 
  10. ^ "Ben Venue Laboratories – Voluntary Shutdown". Drug Safety and Availability. USFDA. 30 November 2011. Retrieved 18 October 2012. 
  11. ^ a b Thomas, Katie (18 October 2012). "Lapses at Big Drug Factories Add to Shortages and Danger". The New York Times. p. A1. 
  12. ^ "Ben Venue Laboratories, Inc to Cease Production" (Press release). Ben Venu Laboratories. 3 October 2013. Archived from the original on 4 October 2013. 
  13. ^ "Pipeline". Boehringer Ingelheim. Retrieved 12 September 2013. 
  14. ^
  15. ^ "Boehringer Ingelheim pays $95 million to settle whistleblower case" (Press release). Phillips & Cohen. 25 October 2012. 
  16. ^ Thomas, Katie (28 May 2014). "$650 Million to Settle Blood Thinner Lawsuits". The New York Times. 

External links[edit]